Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH

04-06-2020 | EULAR 2020 conference hub | Conference coverage | Video

Expert commentary: The EXCEED trial

Laura Coates comments on the results from the EXCEED trial, which showed that secukinumab has similar musculoskeletal efficacy to adalimumab in biologic-naïve patients with psoriatic arthritis (3:51).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read the transcript

Related content

07-05-2020 | Psoriatic arthritis | Highlight | News

EXCEED: Similar musculoskeletal benefits with secukinumab vs adalimumab in PsA

05-06-2020 | EULAR 2020 | Conference coverage | Video

Researcher comment: The EXCEED trial
Image Credits